NCT01118286已完成不适用
AdADOSE - Antihypertensive Treatment With Adalat® in Different Doses and Combination Therapy
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Bayer
- 入组人数
- 4,497
- 主要终点
- Evaluation of treatment success (lowering of blood pressure in mmHg) in adult hypertensive patients
研究概览
简要总结
To investigate the therapeutic effectiveness of long acting nifedipine containing combination therapy in the treatment of hypertensive patients.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Previously untreated hypertensive patients starting with combination therapy containing nifedipine or
- •Insufficiently controlled hypertensive pts. receiving nifedipine as an add-on to existing non-CCB (calcium-channel-blocker) containing antihypertensive therapy
排除标准
- •None. Exclusion criteria are defined by contraindications and precautions as stated in the local product information.
研究组 & 干预措施
Group 1
干预措施: Nifedipine (Adalat, BAYA1040) (Drug)
结局指标
主要结局
Evaluation of treatment success (lowering of blood pressure in mmHg) in adult hypertensive patients
时间窗: After three months
次要结局
未报告次要终点
研究者
相似试验
已完成
3 期
Perindopril Amlodipine for the Treatment of HypertensionEssential HypertensionNCT01556997Symplmed Pharmaceuticals LLC837
已完成
4 期
Losartan and HCTZ and Amlodipine vs Atenolol and Amlodipine (0954A-309)(COMPLETED)HypertensionNCT00140959Organon and Co120
已完成
1 期
Oral Nifedipine to Treat Iron OverloadHemochromatosisIron OverloadThalassemiaNCT00712738National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)6
已完成
2 期
Efficacy and Safety of Amlodipine and Losartan in Patients With Essential HypertensionHypertensionNCT00942344Hanmi Pharmaceutical Company Limited320
已完成
3 期
Fimasartan/Amlodipine Combination Phase IIIEssential HypertensionNCT02152306Boryung Pharmaceutical Co., Ltd143